SEARCH

SEARCH BY CITATION

References

  • 1
    Ceciliani F, Pocacqua V. The acute phase protein alpha1-acid glycoprotein: a model for altered glycosylation during diseases. Curr Protein Pept Sci 2007; 8: 91108.
  • 2
    Fitos I, Visy J, Zsila F, Mady G, Simonyi M. Selective binding of imatinib to the genetic variants of human alpha1-acid glycoprotein. Biochim Biophys Acta 2006; 1760: 17041712.
  • 3
    Gambacorti-Passerini C, Barni R, le Cortre CP, Zucchetti M, Cabrita G, Cleris L, Rossi F, Gianazza E, Brueggen J, Cozens R, Pioltelli P, Pogliani E, Corneo G, Formelli F, D'Incalci M. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 2000; 92: 16411650.
  • 4
    Kretz O, Weiss HM, Schumacher MM, Gross G. In vitro blood distribution and plasma protein binding of the tyrosine kinase inhibitor imatinib and its active metabolite, CGP74588, in rat, mouse, dog, monkey, healthy humans and patients with acute lymphatic leukaemia. Br J Clin Pharmacol 2004; 58: 212216.
  • 5
    Smith KD, Paterson S. Binding of alpha-1-acid glycoprotein to imatinib following increased dosage of drug. Haematologica 2005; 90: (Suppl.): ELT01.
  • 6
    Kwong TC. Free drug measurements: methodology and clinical significance. Clin Chim Acta 1985; 151: 193216.
  • 7
    Bailey DN, Briggs JR. The binding of selected therapeutic drugs to human serum alpha-1 acid glycoprotein and to human serum albumin in vitro. Ther Drug Monit 2004; 26: 4043.
  • 8
    Kremer JM, Wilting J, Janssen LH. Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev 1988; 40: 147.
  • 9
    Svensson CK, Woodruff MN, Baxter JG, Lalka D. Free drug concentration monitoring in clinical practice. Rationale and current status. Clin Pharmacokinet 1986; 11: 450469.
  • 10
    Petain A, Kattygnarath D, Azard J, Chatelut E, Delbaldo C, Geoerger B, Barrois M, Seronie-Vivien S, LeCesne A, Vassal G. Population pharmacokinetics and pharmacogenetics of imatinib in children and adults. Clin Cancer Res 2008; 14: 71027109.
  • 11
    Zsila F, Fitos I, Bencze G, Keri G, Orfi L. Determination of human serum alpha1-acid glycoprotein and albumin binding of various marketed and preclinical kinase inhibitors. Curr Med Chem 2009; 16: 19641977.
  • 12
    Duche JC, Herve F, Tillement JP. Study of the expression of the genetic variants of human alpha1-acid glycoprotein in healthy subjects using isoelectric focusing and immunoblotting. J Chromatogr B Biomed Sci Appl 1998; 715: 103109.
  • 13
    Herve F, Duche JC, Jaurand MC. Changes in expression and microheterogeneity of the genetic variants of human alpha1-acid glycoprotein in malignant mesothelioma. J Chromatogr B Biomed Sci Appl 1998; 715: 111123.
  • 14
    Rowland M. Protein binding and drug clearance. Clin Pharmacokinet 1984; 9: (Suppl. 1): 1017.
  • 15
    Dasgupta A. Clinical utility of free drug monitoring. Clin Chem Lab Med 2002; 40: 986993.
  • 16
    Delbaldo C, Chatelut E, Re M, Deroussent A, Seronie-Vivien S, Jambu A, Berthaud P, Le CA, Blay JY, Vassal G. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res 2006; 12: (20 Pt 1): 60736078.
  • 17
    Widmer N, Decosterd LA, Csajka C, Leyvraz S, Duchosal MA, Rosselet A, Rochat B, Eap CB, Henry H, Biollaz J, Buclin T. Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein. Br J Clin Pharmacol 2006; 62: 97112.
  • 18
    Widmer N, Decosterd LA, Leyvraz S, Duchosal MA, Rosselet A, biec-Rychter M, Csajka C, Biollaz J, Buclin T. Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. Br J Cancer 2008; 98: 16331640.
  • 19
    Haouala A, Zanolari B, Rochat B, Montemurro M, Zaman K, Duchosal MA, Ris HB, Leyvraz S, Widmer N, Decosterd LA. Therapeutic drug monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877: 19821996.
  • 20
    FDA. 2001 Homepage. Guidance for industry: bioanalytical method validation [online]. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf (last accessed 14 May 2012).
  • 21
    Fayet A, Beguin A, de Tejada BM, Colombo S, Cavassini M, Gerber S, Eap CB, Telenti A, Buclin T, Biollaz J, Decosterd LA. Determination of unbound antiretroviral drug concentrations by a modified ultrafiltration method reveals high variability in the free fraction. Ther Drug Monit 2008; 30: 511522.
  • 22
    Streit F, Binder L, Hafke A, Brandhorst G, Braulke F, Haase D, Armbrust T, Cameron S, Ramadori G, Oellerich M, Walson P. Use of total and unbound imatinib and metabolite LC-MS/MS assay to understand individual responses in CML and GIST patients. Ther Drug Monit 2011; 33: 632643.
  • 23
    Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, Benson K, Leighton J, Kim SK, Wood R, Rothmann M, Chen G, U KM, Staten AM, Pazdur R. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 2002; 8: 935942.
  • 24
    Peng B, Dutreix C, Mehring G, Hayes MJ, Ben-Am M, Seiberling M, Pokorny R, Capdeville R, Lloyd P. Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. J Clin Pharmacol 2004; 44: 158162.
  • 25
    Belpaire FM, Braeckman RA, Bogaert MG. Binding of oxprenolol and propranolol to serum, albumin and alpha 1-acid glycoprotein in man and other species. Biochem Pharmacol 1984; 33: 20652069.
  • 26
    MacKichan J. Influence of protein binding and use of unbound (free) drug concentrations. In: Applied Pharmacokinetics and Pharmacodynamics: Principles of Therapeutic Drug Monitoring, eds Burton M , Shaw L , Schentag JJ , Evans W , Wilkins LW . Baltimore, MD: Lippincott, Williams and Wilkins, 2006; 82113.
  • 27
    Lagneau F, Marty J, Beyne P, Tod M. Physiological modeling for indirect evaluation of drug tissular pharmacokinetics under non-steady-state conditions: an example of antimicrobial prophylaxis during liver surgery. J Pharmacokinet Pharmacodyn 2005; 32: 132.
  • 28
    Son DS, Hariya S, Shimoda M, Kokue E. Contribution of alpha 1-acid glycoprotein to plasma protein binding of some basic antimicrobials in pigs. J Vet Pharmacol Ther 1996; 19: 176183.
  • 29
    Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9: 503512.
  • 30
    Schmidli H, Peng B, Riviere GJ, Capdeville R, Hensley M, Gathmann I, Bolton AE, Racine-Poon A. Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study. Br J Clin Pharmacol 2005; 60: 3544.
  • 31
    Judson I, Ma P, Peng B, Verweij J, Racine A, di Paola ED, van Glabbeke M, Dimitrijevic S, Scurr M, Dumez H, van Oosterom A. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 2005; 55: 379386.
  • 32
    Menon-Andersen D, Mondick JT, Jayaraman B, Thompson PA, Blaney SM, Bernstein M, Bond M, Champagne M, Fossler MJ, Barrett JS. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults. Cancer Chemother Pharmacol 2009; 63: 229238.
  • 33
    Cortes JE, Egorin MJ, Guilhot F, Molimard M, Mahon FX. Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia. Leukemia 2009; 23: 15371544.
  • 34
    Larson RA, Druker BJ, Guilhot F, O'Brien SG, Riviere GJ, Krahnke T, Gathmann I, Wang Y. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008; 111: 40224028.
  • 35
    Yoo C, Ryu MH, Kang BW, Yoon SK, Ryoo BY, Chang HM, Lee JL, Beck MY, Kim TW, Kang YK. Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib. J Clin Oncol 2010; 28: 15541559.
  • 36
    Ogawa R, Echizen H. Clinically significant drug interactions with antacids: an update. Drugs 2011; 71: 18391864.
  • 37
    Sparano BA, Egorin MJ, Parise RA, Walters J, Komazec KA, Redner RL, Beumer JH. Effect of antacid on imatinib absorption. Cancer Chemother Pharmacol 2009; 63: 525528.
  • 38
    L.Trainor G. The importance of plasma protein binding in drug discovery. Exp Opin Drug Discov. 2007; 2: 5164.
  • 39
    Denko CW, Gabriel P. Age and sex related levels of albumin, ceruloplasmin, alpha 1 antitrypsin, alpha 1 acid glycoprotein, and transferrin. Ann Clin Lab Sci 1981; 11: 6368.